Timber pharmaceuticals announces fast track designation granted by fda for tmb-001 in severe subtypes of congenital ichthyosis

Company expects to launch pivotal phase 3 ascend clinical trial to evaluate tmb-001 within the next 60 days
TMBR Ratings Summary
TMBR Quant Ranking